Skip to main content

Retinal Degenerative Diseases

Mechanisms and Experimental Therapy

  • Conference proceedings
  • © 2014

Overview

Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 801)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

eBook USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

About this book

This book will contain the proceedings of the XV International Symposium on Retinal Degeneration (RD2012).  A majority of those who will speak and present posters at the meeting will contribute to this volume.  The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70.  The RD Symposium will focus on the exciting new developments aimed at understanding these diseases and providing therapies for them.  Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the “best” and “most important” meetings in the field.

 

The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy.

 

While advances in these areas of retinal degenerations will be described, there will be many new topics that either were in their infancy or did not exist at the time of the last RD Symposium, RD2010.  These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials.

 

The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases andneurodegenerations, in general.  It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS.  Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those will be reported at the RD2010 meeting and included in the proposed volume.  We anticipate the excitement of those working in the field and those afflicted with retinal degenerations will be reflected in the volume.

Similar content being viewed by others

Keywords

Table of contents (106 papers)

  1. Basic Processes: Development, Physiology and Function

  2. Basic Processes: RPE

  3. Basic Processes: Methodology

Editors and Affiliations

  • Department of Ophthalmology, University of Florida, Gainesville, USA

    John D. Ash

  • University Hospital Zurich, Zurich, Switzerland

    Christian Grimm

  • Cole Eye Institute at the Cleveland Clin Division of Ophthalmology, Cleveland, USA

    Joe G. Hollyfield

  • Dean A. McGee Eye Inst., University of Oklahoma Health Science Center, Oklahoma City, USA

    Robert E. Anderson

  • Beckman Vision Center, University of California, San Francisco School of Medicine, San Francisco, USA

    Matthew M. LaVail

  • Department of Ophthalmology, Duke University Medical Center, Durham, USA

    Catherine Bowes Rickman

Bibliographic Information

  • Book Title: Retinal Degenerative Diseases

  • Book Subtitle: Mechanisms and Experimental Therapy

  • Editors: John D. Ash, Christian Grimm, Joe G. Hollyfield, Robert E. Anderson, Matthew M. LaVail, Catherine Bowes Rickman

  • Series Title: Advances in Experimental Medicine and Biology

  • DOI: https://doi.org/10.1007/978-1-4614-3209-8

  • Publisher: Springer New York, NY

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature 2014

  • Hardcover ISBN: 978-1-4614-3208-1Published: 25 March 2014

  • Softcover ISBN: 978-1-4939-5276-2Published: 03 September 2016

  • eBook ISBN: 978-1-4614-3209-8Published: 24 March 2014

  • Series ISSN: 0065-2598

  • Series E-ISSN: 2214-8019

  • Edition Number: 1

  • Number of Pages: LXI, 862

  • Number of Illustrations: 1 b/w illustrations, 187 illustrations in colour

  • Topics: Ophthalmology, Neurosciences, Geriatrics/Gerontology, Human Genetics, Gene Therapy

Publish with us